Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4794224
Max Phase: Preclinical
Molecular Formula: C75H104N18O24
Molecular Weight: 1641.76
Molecule Type: Unknown
Associated Items:
ID: ALA4794224
Max Phase: Preclinical
Molecular Formula: C75H104N18O24
Molecular Weight: 1641.76
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H]1CNC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN)NC(=O)[C@H]2CCCCN2C1=O
Standard InChI: InChI=1S/C75H104N18O24/c1-3-4-5-6-7-8-9-23-58(96)83-49(29-41-35-79-45-20-13-11-18-43(41)45)70(112)89-50(30-57(77)95)71(113)91-53(33-63(104)105)72(114)92-54-36-80-65(107)48(28-40-34-78-44-19-12-10-17-42(40)44)88-68(110)47(24-25-60(98)99)85-73(115)55(38-94)84-59(97)37-81-66(108)51(31-61(100)101)87-64(106)39(2)82-69(111)52(32-62(102)103)90-67(109)46(21-16-26-76)86-74(116)56-22-14-15-27-93(56)75(54)117/h10-13,17-20,34-35,39,46-56,78-79,94H,3-9,14-16,21-33,36-38,76H2,1-2H3,(H2,77,95)(H,80,107)(H,81,108)(H,82,111)(H,83,96)(H,84,97)(H,85,115)(H,86,116)(H,87,106)(H,88,110)(H,89,112)(H,90,109)(H,91,113)(H,92,114)(H,98,99)(H,100,101)(H,102,103)(H,104,105)/t39-,46+,47+,48-,49+,50-,51+,52+,53+,54+,55-,56-/m1/s1
Standard InChI Key: OHDDDVNOHIUUNX-UERWZLDXSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1641.76 | Molecular Weight (Monoisotopic): 1640.7471 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Kleijn LH,Oppedijk SF,'t Hart P,van Harten RM,Martin-Visscher LA,Kemmink J,Breukink E,Martin NI. (2016) Total Synthesis of Laspartomycin C and Characterization of Its Antibacterial Mechanism of Action., 59 (7): [PMID:26967152] [10.1021/acs.jmedchem.6b00219] |
Source(1):